Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
20.1 ^USD	+0.35%		-1.28%	-30.47%

Mar. 06	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
Feb. 29	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

August 04, 2023 at 07:00 am EDT

Fulgent Genetics, Inc. provided earnings guidance for the third quarter of 2023 and full year 2023. For the quarter, the company expected Core Revenue of approximately $65 million.

For the full year 2023, the company expected Core Revenue of approximately $260 million and GAAP loss of approximately $2.15 per share.

Latest news about Fulgent Genetics, Inc.

Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	Mar. 06	MT
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	Feb. 29	MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	Feb. 28	CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Transcript : Fulgent Genetics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 Revenue $70.5M	Feb. 28	MT
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 EPS $0.28	Feb. 28	MT
Cooper Unit, Fulgent Genetic to Offer Newborn Genetic Screening Panels	Feb. 09	MT
Cord Blood Registry by CooperSurgical, Inc. and Fulgent Genetics, Inc. Launch Innovative Genetic Testing	Feb. 09	CI
UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	Dec. 07	MT
Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting	Nov. 03	CI
Transcript : Fulgent Genetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023	Nov. 03
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	Nov. 03	CI
Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2023	Nov. 03	CI
Insider Sell: Fulgent Genetics	23-08-30	MT
Sector Update: Health Care Stocks Steady Premarket Friday	23-08-04	MT
Transcript : Fulgent Genetics, Inc., Q2 2023 Earnings Call, Aug 04, 2023	23-08-04
Fulgent Genetics Swings to Loss in Q2, Revenue Declines; Raises Guidance; Shares Surge 10% Pre-Bell	23-08-04	MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	23-08-04	CI
Fulgent Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023	23-08-04	CI
North American Morning Briefing : Stocks Seen -2-	23-08-04	DJ
Fulgent Genetics, Inc.(NasdaqGM:FLGT) added to Russell 2000 Value-Defensive Index	23-06-23	CI

Chart Fulgent Genetics, Inc.

Duration

Period

More charts

Company Profile

Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.

Sector

Healthcare Facilities & Services

Calendar

2024-05-03 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fulgent Genetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

20.1 USD

Average target price

26.67 USD

Spread / Average Target

+32.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
FULGENT GENETICS, INC.	-30.47%	601M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories